October 10 from 1:00 pm – 1:45 pm HST
Supported By: Veracyte, Inc.
UIP is a critical factor in differentiating IPF from other ILDs and is associated with a poor prognosis in non IPF ILDs. Histopathologic UIP is frequently undetected on HRCT and additional genomic information may be helpful for a more confident and earlier identification of UIP. ILD experts will discuss UIP as a diagnostic entity, and how to incorporate the Envisia Genomic Classifier as part of your workup for a more confident diagnosis and prognosis for patients with ILD, including new data demonstrating how the classifier can predict clinical progression in fibrotic ILD. The Envisia Classifier is performed using a transbronchial biopsy to detect a genomic UIP pattern with a high specificity of 91%. This is a non-CME event and does not qualify for CME or CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2023 conference sessions.
This event is not an endorsement by CHEST and does not reflect the views or opinions of CHEST.
William Bulman, MD
Medical Director, Pulmonary (Lung Cancer & ILD)
South San Francisco, CA
Tejaswini Kulkarni, MD
University of Alabama at Birmingham
Associate Professor of Medicine & Director, Interstitial Lung Disease Program
Joseph A. Lasky, MD, FCCP
Tulane University Medical Center
Professor of Medicine & Pulmonary/Critical Care Section Chief
New Orleans, LA